Outcome of Cyto Reductive Prostatectomy and ADT and Metastasis-Directed Therapy (MDT) in Patients with Oligometastatic Prostate Cancer: A Prospective Cohort

Objective: We wanted to evaluate the efficacy and safety of a new treatment Oligosmetastatic prostate cancer (OMPC) with multimodal approach including local primary tumor therapy, in form Cytoreductive Prostatectomy, metastasis-directed therapy (MDT), hormonal . Methods: reviewed data patients Oligometastatic Prostate Cancer(OMPC) at diagnosis treated our institutions ADT followed by Prostatectomy (CP) or without metastases-directed radiotherapy. In this prospective cohort study, 19 underwent radical routine Lymphadenectomy, Degarelix, Aberateron Prednisolone neoadjuvant setting during period Jan 2016 - March 2021. Of these,05 (26.31%) received stereotactic body radiation (SBRT) all metastatic sites as MDT addition above protocol. Results: The median follow-up was 46.2 months. Perioperative outcomes, clinical progression, cancer-specific mortality (CSM) were evaluated. Median age 72 yr. operative time, blood loss, length hospitalization 176 min, 850 ml, 6 d, respectively. Overall, two (10.52%) experienced grade 3 complications postoperative period. All transfusions. 15 (78.94%) 8 (42.10%) had lymph node invasion positive surgical margins, Adjuvant Radiation Therapy androgen deprivation administered (42.10%)who confirmed margin Positive status. patients, 3-year castration-resistant (CRPC)-free survival was100%. Our findings support effectiveness (C P) highly selected PCa bone metastases long-term Conclusion: This Prospective revealed feasibility combining prostatectomy radiotherapy for newly-diagnosed Prostatic Cancer. strategy has potential delay progression CRPC. Bangladesh J. Urol. 2021; 24(2): 146-154